Summary
The cytokinetic response of three murine (AC) and human (GB-1 and GB-2) glioma cell lines to cis-dichlorodiammineplatinum (II) (CDDP) was investigated by flow cytometry. Using the 5-bromodeoxyuridine (BrdU)-Hoechst technique, percentages of cultured glioma cells in the various phases of the cell cycle, and relative phase duration were calculated. This technique proved to be a rapid and easily performed method to characterize phase length and transition rate for the complete cell cycle. In the presence of CDDP IC10 (a concentration in which 10% inhibition of cell growth be induced as compared to controls), perturbations of the cell cycle in AC and GB-1 cells included G2 delay or block, decreased transit velocity from G1 to S phase, and prolongation of G1 phase. The mean cell cycle time increased 1.4 times in AC and 1.6 times in GB-1 as compared to controls. In CDDP IC50-treated GB-2 cells, the mean cell cycle time was prolonged three times longer than control: however, duration of each phase could not be calculated because of significant perturbation of cell cycle. These results suggest that CDDP influences glioma cells at the G1/S boundary and in the G2 phase, resulting in prolongation of the G1 phase and, to a minor degree, in block of the G2 phase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Göhde W, Schumann J, Buchner T, Otto F, Barlogie B: Pulse cytophotometry: its application in tumor cell biology and clinical oncology. In: P Mullany, M Mendelsohn, M Melamed (eds), Particle Flow Analysis 1979, pp 599–620
Hoshino T: Therapeutic implications of brain tumor cell kinetics. Natl Cancer Inst Monogr 46:29–35, 1977
Hoshino T, Wilson CB: Cell kinetic analysis of human malignant brain tumors (gliomas). Cancer 44:956–962, 1979
Hoshino T, Nagashima T, Murovic J, Levin EM, Levin VA, Rupp SM: Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. Cytometry 6:627–632, 1985
Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, Stein H: Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol (Berl) 74:179–182, 1987
Latt SA: Microfluorometric detection of deoxyribonucleic acid replication in human metaphase chromosomes. Proc Natl Acad Sci USA 70:3395–3399, 1973
Igarashi K, Ikeyama S, Takeuchi M, Sugino Y: Morphological changes in rat glioma cells caused by adenosine cyclic 3′,5′-monophosphate. Cell Struct Funct 3:103–112, 1978
Kaba K, Tani E, Morimura T, Matsumoto T: Potentiation of vincristine effect in human and murine gliomas by calcium channel blockers or calmodulin inhibitors. J Neurosurg 63:905–911, 1985
Arndt-Jovin DJ, Jovin TM: Analysis and sorting of living cells according to deoxyribonucleic acid content. J Histochem Cytochem 25:585–589, 1977
Gray JW. Cell-cycle analysis of perturbed cell populations: Computer simulation of sequential DNA distributions. Cell Tissue Kinet 9:499–516, 1976
Böhmer RM: Flow cytometric cell cycle analysis using the quenching of 33258 Hoechst fluorescence by bromodeoxyuridine incorporation. Cell Tissue Kinet 12:101–110, 1979
Sekaly RP, MacDonald HR, Zaech P, Nabholz M: Cell cycle regulation of cloned cytolytic T cells by T cell growth factors: Analysis by flow microfluorometry. J Immunol 129:1407–1415, 1982
Baserga RB: The cell cycle. N Engl J Med 304:453–459, 1981
Mauro F, Göhde W, Schumann J, Teodori L, Spano M: Considerations in the design of possible cell cycle effective drugs. Int J Radiat Biol 49:307–333, 1986
Bigner DD: Biology of gliomas: Potential clinical implications of glioma cellular heterogeneity. Neurosurgery 9:320–326, 1981
Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38:2651–2657, 1978
Yung W-KA, Shapiro JR, Shapiro WR: Heterogenous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42:992–998, 1982
Stewart DJ, Grahovac Z, Benoit B, Addison D, Richard MT, Dennery J, Hugenholtz H, Russell N, Peterson E, Maroun JA, Vandenberg T, Hopkins HS: Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diammineplatinum (cisplatin), and 4′-0-demetyl-1–0-(4,6–0–2-thenylidene-β-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary and metastatic brain tumors. Neurosurgery 15:828–833, 1984
Meyn RE, Meistrich ML, White RA: Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation. J Natl Cancer Inst 64:1215–1219, 1980
Drewinko B, Gottlieb JA: Action of the cisdichlorodiammineplatinum (II) (NSC-119875) at the cellular level. Cancer Chemother Rep 59:665–673, 1975
Bergerat J-P, Barlogie B, Göhde W, Johnston DA, Drewinko B: In vitro cytokinetic response of human colon cancer cells to cis-dichlorodiammineplatinum (II). Cancer Res 39:4356–4363, 1979
Drewinko B, Brown BW, Gottlieb JA: The effect of cisdiamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 33:3091–3095, 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morimura, T. Prolongation of G1 phase in cultured glioma cells by cis-dichlorodiammineplatinum (II) (CDDP): Analysis using bromodeoxyuridine (BrdU)-Hoechst technique. J Neuro-Oncol 7, 71–79 (1989). https://doi.org/10.1007/BF00149381
Issue Date:
DOI: https://doi.org/10.1007/BF00149381